EUVIMEDEUVIMED entdecken
Crossref

Design and Development of New Dual Target Agents, Cannabinoid Subtype 2 Receptor (CB2R) Agonists, and Fatty Acid Amide Hydrolase (FAAH) Inhibitors against Neurodegeneration

Giovanni Graziano iD, Francesco Mastropasqua, Annalisa Fanizzi, M Giovanna E Papadopoulos iD, Antonio Laghezza iD, Mariachiara Mammone iD, Gabriella Rosanna Musillo, Giuseppe Felice Mangiatordi iD, Jose Brea iD, Maria Isabel Loza iD, Cas van der Horst, Chiara Riganti iD und 9 weitere

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.6c02401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Giovanni Graziano und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy-Pharmaceutical Sciences, University of Bari ALDO MORO, 70125Bari, Italy. Hauptthemen laut MEDLINE: Amidohydrolases, Receptor, Cannabinoid, CB2, Drug Design, Enzyme Inhibitors. Die Arbeit nennt 67 Literaturangaben. Gefördert von: Agencia Estatal de Investigación, MNESYSA Multiscale integrated approach to the study of nervous system (DN.1553 11.10.2022), European Regional Development Fund (ERDF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As dual modulators of Cannabinoid subtype 2 receptor (CB2R) and fatty acid amide hydrolase (FAAH)an arising therapeutic strategy against diseases based on neuroinflammationwe developed a new series of N-adamantyl-benzamides bearing an anthranilic or salicylic scaffold. Derivatives 18, 22, and 25 emerged as an interesting compromise in terms of CB2R activity, CB2R/CB1R selectivity, and FAAH inhibition. All compounds were potent FAAH inhibitors; 18 and 25 acted as unbiased CB2R agonists with no CB1R affinity, whereas 22 was a CB2R antagonist in the cAMP pathway and partial agonist in β-arrestin-2 recruitment. The three compounds were tested in monocytes and macrophages in resting and activated states and in a human activated microglia model with a potent anti-inflammatory action. These results support the CB2R and FAAH engagement as a promising dual strategy against neuroinflammation providing valuable chemical tools for probing the structural determinants underlying CB2R binding, long residence time, and biased signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmidohydrolasesReceptor, Cannabinoid, CB2Drug DesignEnzyme InhibitorsBenzamidesNeurodegenerative DiseasesFatty Acid Amide HydrolasesHumansStructure-Activity RelationshipAnimalsMicroglia

Stichwörter der Autor:innen

CB2RFAAHcannabinoid receptor subtype 2dual drugsfatty acid amide hydrolaseinflammationmultitarget ligands

Substanzen

Fatty Acid Amide HydrolasesAmidohydrolasesReceptor, Cannabinoid, CB2Enzyme InhibitorsBenzamides

Autor:innen und Institutionen

  • Department of Pharmacy-Pharmaceutical Sciences, University of Bari ALDO MORO, 70125Bari, Italy.
  • Institute of Crystallography, National Research Council of Italy, 70126Bari, Italy.
  • Innopharma Screening Platform, BioFarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782Santiago de Compostela, Spain.
  • Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain.
  • Oncode Institute & Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), Leiden University, 2311Leiden, The Netherlands.
  • Department of Oncology, University of Torino, 10126Torino, Italy.

ORCID-Profile: Giovanni Graziano, M Giovanna E Papadopoulos, Antonio Laghezza, Mariachiara Mammone, Giuseppe Felice Mangiatordi, Jose Brea, Maria Isabel Loza, Chiara Riganti, Maria Grazia Perrone, Laura H Heitman, Nicola Antonio Colabufo, Angela Stefanachi, Carmen Abate, Marialessandra Contino

Förderung

  • Agencia Estatal de Investigación
  • MNESYSA Multiscale integrated approach to the study of nervous system (DN.1553 11.10.2022)
  • European Regional Development Fund (ERDF)
  • NextGeneration EU_PNRR _ M4.C2
  • Xunta de Galicia
  • Ministry of University and Research (MUR)
  • National Recovery and Resilience Plan (NRRP)

Zitieren

APA

Graziano, G., Mastropasqua, F., Fanizzi, A., Papadopoulos, M. G. E., Laghezza, A., Mammone, M., Musillo, G. R., Mangiatordi, G. F., Brea, J., Loza, M. I., van der Horst, C., Riganti, C., Esposito, D., Perrone, M. G., Leonetti, F., Heitman, L. H., Colabufo, N. A., Stefanachi, A., Abate, C., …, & Contino, M. (2026). Design and Development of New Dual Target Agents, Cannabinoid Subtype 2 Receptor (CB2R) Agonists, and Fatty Acid Amide Hydrolase (FAAH) Inhibitors against Neurodegeneration. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02401

Vancouver

Graziano G, Mastropasqua F, Fanizzi A, Papadopoulos MGE, Laghezza A, Mammone M, et al. Design and Development of New Dual Target Agents, Cannabinoid Subtype 2 Receptor (CB2R) Agonists, and Fatty Acid Amide Hydrolase (FAAH) Inhibitors against Neurodegeneration. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c02401

BibTeX
@article{Graziano2026,
  author = {Graziano, Giovanni and Mastropasqua, Francesco and Fanizzi, Annalisa and Papadopoulos, M Giovanna E and Laghezza, Antonio and Mammone, Mariachiara and Musillo, Gabriella Rosanna and Mangiatordi, Giuseppe Felice and Brea, Jose and Loza, Maria Isabel and van der Horst, Cas and Riganti, Chiara and Esposito, Daniela and Perrone, Maria Grazia and Leonetti, Francesco and Heitman, Laura H and Colabufo, Nicola Antonio and Stefanachi, Angela and Abate, Carmen and Ligresti, Alessia and Contino, Marialessandra},
  title = {Design and Development of New Dual Target Agents, Cannabinoid Subtype 2 Receptor (CB2R) Agonists, and Fatty Acid Amide Hydrolase (FAAH) Inhibitors against Neurodegeneration},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c02401}
}
Kostenlos starten →